ARRY-520 demonstrated single agent activity in heavily pretreated patients, with 19 months median Overall Survival and a 16% Overall Response Rate. These results are similar to those for recently ...
The notes will be general senior unsecured obligations of Array and will pay interest semi-annually. The principal amount, interest rate, conversion rate, offering price and other terms will be ...
Array BioPharma and Celgene today announced having entered a collaboration through which the companies will use the former firm’s preclinical development program, targeting a novel inflammation ...
BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK ...
Array BioPharma Inc. has announced the commencement of drug discovery collaboration with Ono Pharmaceutical Co., Ltd. to create small molecule drug candidates against a series of kinases selected by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results